KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Net Margin (2017 - 2025)

Sarepta Therapeutics has reported Net Margin over the past 12 years, most recently at 63.86% for Q4 2025.

  • For Q4 2025, Net Margin fell 9042.0% year-over-year to 63.86%; the TTM value through Dec 2025 reached 32.26%, down 4552.0%, while the annual FY2025 figure was 32.45%, 4572.0% down from the prior year.
  • Net Margin for Q4 2025 was 63.86% at Sarepta Therapeutics, down from 45.06% in the prior quarter.
  • Over five years, Net Margin peaked at 123.76% in Q4 2021 and troughed at 2348.35% in Q1 2023.
  • A 5-year average of 241.96% and a median of 35.24% in 2021 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: tumbled -229854bps in 2023 and later soared 235719bps in 2024.
  • Year by year, Net Margin stood at 123.76% in 2021, then crashed by -85bps to 18.29% in 2022, then crashed by -77bps to 4.23% in 2023, then skyrocketed by 527bps to 26.56% in 2024, then plummeted by -340bps to 63.86% in 2025.
  • Business Quant data shows Net Margin for SRPT at 63.86% in Q4 2025, 45.06% in Q3 2025, and 32.92% in Q2 2025.